Charles Le. Vogel

Charles Le. Vogel's AcademicInfluence.com Rankings

Charles Le. Vogel

Philosophy

#9466

World Rank

#13030

Historical Rank

Logic

#6439

World Rank

#7956

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Charles Le. Vogel's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is Charles Le. Vogel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Charles Le. Vogel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer (2002) (3080)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. (1999) (2850)
Aspergillosis. The spectrum of the disease in 98 patients. (1970) (958)
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. (1999) (782)
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. (2011) (645)
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. (1997) (559)
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. (2009) (511)
Adjuvant docetaxel for node-positive breast cancer. (2005) (508)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. (2005) (478)
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma (1998) (459)
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. (1996) (397)
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. (2003) (359)
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. (2005) (349)
Liver cell dysplasia: a premalignant condition (1973) (300)
Kaposi's sarcoma in Uganda: A clinico‐pathological study (1971) (292)
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. (2001) (262)
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. (2001) (222)
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer (2012) (221)
Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. (1995) (218)
First-Line Herceptin® Monotherapy in Metastatic Breast Cancer (2001) (207)
A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma (1997) (206)
HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. (2013) (199)
Secretion of methotrexate into human milk. (1972) (195)
Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. (1995) (189)
Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. (1995) (183)
Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma. (1970) (177)
Final 5‐year results of Z‐FAST trial (2012) (171)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. (2004) (171)
Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial (2002) (158)
Immunological effects of BCG in malignant melanoma: two modes of administration compared. (1972) (137)
Familial chronic lymphocytic leukemia. (1969) (136)
Myelofibrosis in chronic granulocytic leukemia. (1971) (123)
A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project (1977) (119)
Kaposi's sarcoma: a comparison of classical, endemic, and epidemic forms. (1984) (117)
Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. (1995) (115)
Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid (2012) (114)
Focused microwave phased array thermotherapy for primary breast cancer (2002) (111)
Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. (1991) (103)
Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience (2002) (99)
Effects of high dose raloxifene in selected patients with advanced breast carcinoma (2000) (98)
Hepatitis B virus infection and primary hepatocellular carcinoma. (1977) (97)
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer (2007) (92)
Burkitt's tumor in the United States (1969) (92)
Kaposi's sarcoma: a new model in the search for viruses associated with human malignancies. (1972) (90)
Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma. (1972) (90)
A staging system for hepatocellular carcinoma: Prognostic factors in Ugandan patients (1975) (90)
Survival after first recurrence of breast cancer. The miami experience (1992) (90)
Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? (2012) (89)
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. (2004) (81)
A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States (1977) (80)
Effect of surgical and chemotherapeutic treatment on alpha‐fetoprotein levels in patients with hepatocellular carcinoma (1976) (79)
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. (2004) (76)
Phase II study of gemcltablne in patients with metastatic breast cancer (1997) (72)
Clinical Experience with Trastuzumab (Herceptin) (2003) (69)
A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. (2009) (69)
First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody) (2000) (69)
Pneumocystis carinii pneumonia. (1958) (68)
Dual HER2-targeted approaches in HER2-positive breast cancer (2011) (64)
Erratum: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials (Cancer (1998) 83 (1142-1152)) (1999) (63)
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy (2013) (60)
Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. (1998) (60)
Toremifene for breast cancer: a review of 20 years of data. (2014) (59)
Studies on levamisole--induced agranulocytosis. (1980) (55)
Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer. (2009) (54)
Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. (2008) (54)
Monotherapy of metastatic breast cancer: a review of newer agents. (1999) (50)
Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look. (1972) (44)
Treatment of kaposi's sarcoma with a combination of actinomycin D and vincristine (1973) (44)
Immunological Studies in Ugandan Patients with Hepatocellular Carcinoma (1973) (44)
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. (1997) (44)
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer (2014) (43)
Treatment of Kaposi's sarcoma by combination of actinomycin‐D, vincristine and imidazole carboxamide (NSC‐45388): Results of a randomized clinical trial (1974) (43)
Hepatitis-associated antigen and antibody in hepatocellular carcinoma: results of a continuing study. (1972) (42)
Aspergillus lobar pneumonia. (1969) (41)
Treatment of Kaposi's sarcoma with actinomycin‐D and cyclophosphamide: Results of a randomtzed cltnical trial (1971) (40)
Serum alpha‐fetoprotein in 184 ugandan patients with hepatocellular carcinoma. Clinical, laboratory, and histopathologic correlations (1974) (39)
Adjuvant systemic therapy of primary breast cancer (1988) (37)
Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature (2015) (37)
Hepatitis-associated Antigen and Antibody in Uganda: Correlation of Serological Testing with Histopathology (1972) (37)
A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer (1983) (35)
Weekly Paclitaxel in Women Age 65 and Above with Metastatic Breast Cancer* (2002) (33)
Sarcomas and multiple polyposis in a kindred. A genetic variety of hereditary polyposis? (1968) (31)
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. (2016) (31)
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. (2007) (31)
Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study (1998) (31)
Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience (2004) (31)
Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis (2010) (30)
Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. (1984) (30)
A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. (2009) (29)
Toxoplasma serology in patients with malignant diseases of the reticuloendothelial system (1969) (28)
International symposium on hepatocellular carcinoma—kampala, uganda (July 1971) (1972) (28)
Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. (2005) (28)
A review of vinorelbine in the treatment of breast cancer. (2001) (27)
Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. (1999) (27)
Ectopic production of human chorionic gonadotropin in ugandan patients with hepatocellular carcinoma (1973) (26)
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors (2016) (26)
High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review. (2009) (25)
Phase II study of oral etoposide for patients with advanced breast cancer (1995) (25)
Hormonal approaches to breast cancer treatment and prevention: an overview. (1996) (25)
Serologic diagnosis of active toxoplasmosis complicating malignant diseases. Usefulness of IgM antibodies and gel‐diffusion (1970) (24)
Needle biopsy in pseudocystis carinii pneumonia. (1969) (24)
Protocollagen proline hydroxylase in sera of Ugandans with hepatocellular carcinoma. (1972) (24)
Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid. (1985) (24)
Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. (1978) (24)
Response to tamoxifen in estrogen receptor‐poor metastatic breast cancer (1987) (22)
Management of locally advanced breast cancer (stage III): a review. (1984) (22)
Phase II clinical trials of BCNU )NSC-409962) and bleomycin (NSC-125066) in the treatment of Kaposi's sarcoma. (1973) (22)
A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. (2009) (22)
Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. (2007) (21)
Trastuzumab plus chemotherapy: convincing survival benefit or not? (2005) (20)
Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors (2004) (19)
Clinical trial of high‐dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature (1988) (19)
Mechanisms of levamisole‐induced granulocytopenia in breast cancer patients (1980) (18)
Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma. (1972) (18)
Burkitt's tumor in the United States. (1969) (17)
Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study. (2001) (17)
Ultrastructural survey of primary liver cell carcinomas from Uganda. (1972) (16)
Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse (2015) (16)
Glutamate dehydrogenase activity related to histopathological grade of hepatocellular carcinoma in man. (1974) (16)
Effective treatment of Kaposi's sarcoma with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). (1973) (15)
Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint? (2008) (15)
Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study. (2021) (15)
A phase i study of 4′‐0‐tetrahydropyranyladriamycin: Clinical pharmacology and pharmacokinetics (1990) (15)
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer (2014) (14)
Consensus on Medical Treatment of Metastatic Breast Cancer (2003) (13)
Efficacy of trastuzumab. (2005) (13)
Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients (1980) (12)
Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial. (1986) (12)
JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
Mitogen-induced blastogenesis and receptor mobility inhibition by breast cancer serum with elevated orosomucoid (alpha 1-acid glycoprotein) levels. (1982) (12)
Current status of salvage chemotherapy for refractory advanced breast cancer (1996) (11)
Management of locally recurrent breast cancer (1993) (11)
Cyclophosphamide, adriamycin and 5-fluorouracil (CAF) alternating with a cycle-active regimen in metastatic breast cancer: A randomized southeastern cancer study group trial (1981) (11)
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). (2020) (10)
Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial. (1986) (10)
Suppression of experimental allergic encephalomyelitis by NSC 82196, a new imidazole carboxamide derivative. (1969) (10)
Immunologic studies in American patients with Burkitt-like lymphoma. (1967) (10)
Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial. (1986) (10)
P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry. (2011) (9)
Reported Bone Pain in Cancer Patients Receiving Chemotherapy in Pegfilgrastim Clinical Trials: A Retrospective Analysis. (2009) (9)
Dopa and 5-S-cysteinyldopa in malignant melanoma in Ugandan Africans. (1974) (9)
Evaluation of human chorionic gonadotropin and alpha fetoprotein in benign and malignant testicular disorders. (1978) (9)
The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. (2004) (8)
Update on the current use of hormonals as therapy in advanced breast cancer (2003) (8)
Response to oophorectomy after tamoxifen failure in a premenopausal patient. (1982) (8)
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer (1985) (8)
Evaluation of reported bone pain in patients (pts) receiving chemotherapy in pegfilgrastim clinical trials. (2016) (7)
Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer (2010) (7)
Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1). (2009) (7)
Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors. (1985) (7)
Management of Kaposi's sarcoma. Chemotherapy I. (1981) (7)
Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from herceptin monotherapy (2001) (6)
Rivanol precipitation technique for the detection of alpha-feto-protein. (1972) (6)
Treatment of experimental allergic encephalomyelitis in the rabbit. (1972) (6)
Management of Kaposi’s Sarcoma (1981) (6)
Relationship of estrogen receptor (ER) status to clinical benefit in clinical trials of herceptin (2001) (6)
Response to tamoxifen in estrogen receptor-poor metastatic breast cancer. (1987) (5)
Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule. (1976) (5)
Adjuvant Docetaxel plus Doxorubicin and Cyclophosphamide for Node-Positive Breast Cancer (2005) (5)
Docetaxel-based regimen (TAC) improves DFS and OS over FAC in node positive early breast cancer patients: efficacy, safety and quality of life at 55 month follow-up (2004) (5)
Enhanced Suppression of Experimental Allergic Encephalomyelitis by Combination Chemotherapy with Duazomycin-A and 6-Mercaptopurine∗ (1969) (5)
Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer. (2005) (5)
Randomized double‐blind phase 2 trial of 3 doses of TAS‐108 in patients with advanced or metastatic postmenopausal breast cancer (2012) (5)
Acupuncture for the management of hot flashes in women with early stage breast cancer treated with tamoxifen or an aromatase inhibitor: A pilot study of efficacy, safety and feasibility (2005) (5)
Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy. (1978) (4)
BCIRG 001 molecular analysis: Identification of prognostic factors in patients (pts) receiving adjuvant therapy for node- positive (N+) breast cancer (BC) (2007) (4)
Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer (2019) (4)
A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer. (2015) (4)
Clinical trials of combination chemotherapy with BCNU and vincristine in the treatment of malignant melanoma in Uganda (1973) (4)
Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY). (1980) (4)
Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer (1988) (4)
Blood coagulation and fibrinolysis in Ugandan patients with cirrhosis and hepatocellular carcinoma. (1974) (3)
Updated results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC). (2005) (3)
Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer. (2020) (3)
351 Two randomised trials establishing efficacy and tolerability of arimidex (ZD1033) in the treatment of postmenopausal women with advanced breast cancer (PABC) (1995) (3)
Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients (2019) (3)
Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+ metastatic breast cancer. (2004) (3)
Liver celldysplasia: apremalignant condition (1973) (3)
Abstract PD8-10: Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study (2021) (3)
Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit (2001) (3)
Correlation between estrogen receptors and response to nonhormonal chemotherapy in metastatic breast cancer (1981) (3)
RATIONALE FOR TRIALS STUDYING PEGYLATED LIPOSOMAL DOXORUBICIN IN METASTATIC BREAST CANCER (1997) (3)
Phase II study of alternating cytoreductive and cycle-active combination chemotherapy for metastatic breast cancer. (1979) (2)
Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2 (1999) (2)
Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study. (2012) (2)
Complete response in metastatic breast cancer (1986) (2)
Trastuzumab Monotherapy (2004) (2)
Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer (1984) (2)
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease (2023) (2)
Sequential versus concomitant chemo-hormonal therapy in breast cancer (1982) (2)
Phase I study of misonidazole and cyclophosphamide in solid tumors (1982) (2)
P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study. (2011) (2)
Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. (2013) (2)
Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC) (2017) (2)
Reported Bone Pain in Patients with Breast Cancer Receiving Taxane-Based Chemotherapy in Clinical Trials of Pegfilgrastim.: (2009) (2)
High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): “back to the future.”. (2009) (2)
Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: The Southeastern Cancer Study Group experience (1983) (1)
Safety of zoledronic acid in patients who have previously received bisphosphonate therapy. (2004) (1)
Estrogen priming before progestin therapy in advanced breast cancer (1990) (1)
Phase I clinical trial of weekly intravenous ICRF-187 (NSC 169780): A Southeastern Cancer Study Group trial (1981) (1)
Liver cell dysplasia: a premalignant condition. (1973) (1)
Levamisole granulocytopenia in patients receiving an adjuvant chemoimmunotherapy program after surgery for breast carcinoma with axillary lymph node involvement. (1978) (1)
Recent trends in breast cancer treatment. (1978) (1)
Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial. (1988) (1)
A Phase I Clinical Trial of a Combination of Mitoxantrone, 5‐Fluorouracil, and High‐Dose Leucovorin Given on a Day 1 and Day 8 Schedule to Patients with Metastatic Breast Cancer (1994) (1)
Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature (2022) (1)
High dose oral medroxy-progesterone acetate (HDO-MPA) for advanced breast cancer (BC) (1982) (1)
Systemic therapy of breast cancer--1985. (1985) (1)
The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtypes. (2013) (1)
A randomized, phase II trial of AEZS-108 in chemotherapy refractory triple-negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer. (2013) (1)
A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer (2011) (1)
Maximizing differences in the concanavalin A-induced blastogenic responses of lymphocytes from breast cancer patients and controls by the use of alpha-methyl-D-mannoside. (1982) (1)
Multicenter P hase I I T rial o f W eekly P aclitaxel i n W omen With M etastatic B reast C ancer (2001) (0)
Reply to R.S. Mehta et al (2009) (0)
Sequential (SEQ) versus combination (COMB) hormonal and chemotherapy in post menopausal patients with metastatic breast cancer (1977) (0)
Reply to L.C. Panasci (2009) (0)
Systemic cancer therapy: four decades of progress and some personal perspectives. (1990) (0)
Highlights in metastatic breast cancer from the 2011 San Antonio Breast Cancer Symposium (SABCS). (2012) (0)
Modal Hyperploidy in Human Neoplasia (1974) (0)
Abstract OT2-3-11: Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer (2012) (0)
Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial. (1987) (0)
Decetaxel incombination rhuMAb hr2 for the treatment of cancers. (2000) (0)
Phase I trial of 1,2: 5,6 dianhydrogalactitol (DAGA) (NSC 132-313) administered in a weekly schedule (1976) (0)
Capecitabine plus docetaxel (XT): A first line, phase II clinical trial in metastatic breast cancer. (2006) (0)
Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma (1988) (0)
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. (2023) (0)
Abstract P1-11-05: Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer (2010) (0)
100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study (2021) (0)
A clinical dilemma : isolated breast cancer recurrence and dose intensive chemotherapeutic strategies (1991) (0)
Commentary (Vogel): Trastuzumab in Breast Cancer (2004) (0)
Cisplatin/Epinephrine Injectable Gel for Intratumoral Therapy of Accessible Solid Tumors Including Head and Neck Squamous Cell Carcinoma (1996) (0)
lighttheneedforresearchdesignedtobetterdefinethecon- textinwhichfishoilmaybenefitpatientswithcoronaryartery disease. (2017) (0)
When Can a Salvage Therapy (T-DM1) Take the Lead? (2016) (0)
Efficacy a nd S afety o f T rastuzumab a s a S ingle A gent i n First-Line T reatment o f HER2 -Overexpressing M etastatic Breast C ancer (2011) (0)
Vinorelbine plus capecitabine in a heavily pretreated HER2 negative metastatic breast cancer patient population: MCEPASTEBIN. (2018) (0)
Systemic therapy for breast cancer: changing trends, 1980. (1980) (0)
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy. (2022) (0)
Abstract P1-12-03: Low-dose capecitabine monotherapy in HER-2 negative metastatic breast cancer: a retrospective study. (2012) (0)
Alternating cytoreductive and cycle-active combination chemotherapy in metastatic breast cancer (MBC) (1978) (0)
Letter: Modal hyperploidy in human neoplasia. (1974) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Charles Le. Vogel?

Charles Le. Vogel is affiliated with the following schools: